Interim report 2026
Filed with HKEX · Stock code 2171 · · 81 pages · English
Corporate Information 2 Financial Highlights 3 Business Highlights 4 Management Discussion & Analysis 6 Corporate Governance and Other Information 30 Interim Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income 50 Interim Condensed Consolidated Statement of Financial Position 51 Interim Condensed Consolidated Statement of Changes in Equity 52 Interim Condensed Consolid
CARsgen Therapeutics Holdings Ltd. on 6ix
Earlier from CARsgen Therapeutics
- CARsgen Therapeutics Announces 2026 Interim Results
- CARsgen Announces Approval of Satri-cel, the World's First CAR T-Cell Therapy Product for Solid Tumors
- CARsgen Presents Allogeneic CAR T-cell Products CT0596 and CT1190B at EHA 2026
- Long-term Follow-up Results of CARsgen's Satri-cel as Sequential Therapy After First-Line Treatment for Gastric Cancer Presented at the 2026 ASCO Annual Meeting
- CARsgen Therapeutics Announces 2025 Annual Results
Later from CARsgen Therapeutics
- Voluntary announcement - first patient dose of CT1190B in china phase i registrational trial
- Resignation of non-executive director and non-compliance with rule 3.21 of the listing rules
- List of directors and their roles and functions
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Voluntary announcement - first patient dose of CT0596 in china phase i registrational trial
Follow CARsgen Therapeutics into a list and get an email when it puts out news.
Follow CARsgen Therapeutics